- Home
- RVT vs CGON Comparison
RVT vs CGON Comparison
Compare RVT & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- CGON
- Stock Information
- Founded
- RVT 1986
- CGON 2010
- Country
- RVT United States
- CGON United States
- Employees
- RVT N/A
- CGON N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- CGON
- Sector
- RVT Finance
- CGON
- Exchange
- RVT Nasdaq
- CGON NYSE
- Market Cap
- RVT 1.9B
- CGON 2.1B
- IPO Year
- RVT N/A
- CGON 2024
- Fundamental
- Price
- RVT $14.96
- CGON $26.23
- Analyst Decision
- RVT
- CGON Strong Buy
- Analyst Count
- RVT 0
- CGON 10
- Target Price
- RVT N/A
- CGON $64.44
- AVG Volume (30 Days)
- RVT 243.4K
- CGON 781.7K
- Earning Date
- RVT 01-01-0001
- CGON 08-07-2025
- Dividend Yield
- RVT 7.32%
- CGON N/A
- EPS Growth
- RVT N/A
- CGON N/A
- EPS
- RVT 2.95
- CGON N/A
- Revenue
- RVT N/A
- CGON $662,000.00
- Revenue This Year
- RVT N/A
- CGON N/A
- Revenue Next Year
- RVT N/A
- CGON $25,206.93
- P/E Ratio
- RVT $4.98
- CGON N/A
- Revenue Growth
- RVT N/A
- CGON 224.51
- 52 Week Low
- RVT $11.85
- CGON $14.80
- 52 Week High
- RVT $14.93
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- RVT 55.80
- CGON 50.40
- Support Level
- RVT $14.41
- CGON $25.24
- Resistance Level
- RVT $14.90
- CGON $26.59
- Average True Range (ATR)
- RVT 0.22
- CGON 1.10
- MACD
- RVT -0.02
- CGON -0.12
- Stochastic Oscillator
- RVT 64.61
- CGON 29.83
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.